Lung Cancer in Australia: A Call to Arms for Early Diagnosis and Multidimensional Management
▫️Written by John Keller
✅ Reviewed by Dr. Jenny Hynes on SEPTEMBER 20, 2023
The verdant landscapes of Australia, often emblematic of life and vigour, paradoxically bear witness to a lurking menace: lung cancer. According to the Australian Institute of Health and Welfare (AIHW), this ailment stands tall among its peers, stubbornly retaining its position as one of the top five cancers diagnosed in the country, impacting the daily lives of thousands of Australians each year (AIHW, 2020). Behind these grim statistics are stories of aspirations curtailed, families disrupted, and the palpable cost to our social fabric.
Lung cancer's early detection is monumental. As outlined by *Field & Duffy* in their 2008 study, when identified in its incipient stages, patients have a significantly higher survival rate and access to a broader spectrum of treatment possibilities. Yet, a pertinent challenge remains: elevating public cognizance, ensuring healthcare professionals are consistently on the alert, and fostering research that pushes the boundaries of early diagnostic techniques.
Intertwined with this narrative is the often-understated role of physiotherapy. Beyond surgical and medical treatments, physiotherapy, as highlighted by *Cavalheri et al.* in their 2014 review, has manifested as a beacon of hope, enhancing respiratory function and overall physical wellbeing in lung cancer patients. A holistic approach to care thus emerges, where the objective extends beyond mere survival to achieving a meaningful quality of life.
The spectre of lung cancer, despite its alarming prevalence, is not an insurmountable challenge. Through timely detection, judicious treatment selection, and the inclusion of physiotherapy, we can envision a future where the disease's impact is substantially mitigated.
What Is Lung Cancer?
Lung cancer is a malignancy that originates in the tissues of the lungs, typically in the cells lining the air passages. At its core, lung cancer, like other cancers, is the result of cellular mutations driven by various genetic and environmental factors. When these mutations accumulate, cells begin to grow and divide uncontrollably, ultimately forming a tumor. If unchecked, these cancerous cells can metastasize, or spread, to other parts of the body.
There are primarily two broad categories of lung cancer:
1. Non-small cell lung cancer (NSCLC)
This is the most prevalent type, accounting for approximately 85% of all lung cancer diagnoses (Travis et al., 2015). NSCLC can be further subdivided into various subtypes, including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Each subtype tends to have a distinct pattern of growth and spread, which influences its treatment approach.
2. Small cell lung cancer (SCLC)
Accounting for about 10-15% of all lung cancer cases, SCLC is a more aggressive form of the disease and is closely linked to cigarette smoking (Oser et al., 2015). It often grows rapidly and spreads to other body parts faster than NSCLC.
Understanding the risk factors associated with lung cancer is paramount for both prevention and early detection. The most significant risk factor for lung cancer is smoking tobacco, responsible for nearly 85% of all cases (Hecht, 2012). Other risk factors include exposure to asbestos, radon gas, and other carcinogens, a history of lung disease, and a family history of lung cancer. Being cognizant of these risks can lead to proactive measures, such as regular screenings for those at a higher risk, ultimately improving outcomes and prognosis.
Causes and Risk Factors
Lung cancer, a leading malignancy globally, has an intricate mosaic of causes and risk factors, each contributing uniquely to the likelihood of disease development. Understanding these risk factors aids in formulating strategies for prevention, early detection, and management.
1. Smoking
The most significant risk factor for lung cancer is smoking tobacco, responsible for nearly 85% of all cases (Hecht, 2012). According to the Centers for Disease Control and Prevention (CDC), smokers are 15 to 30 times more likely to get lung cancer or die from lung cancer than non-smokers. It's not just cigarettes, though. Cigar and pipe smoking are almost as likely to cause lung cancer as cigarette smoking (Thun et al., 2008).
2. Exposure to Secondhand Smoke
Passive or involuntary smoking also raises lung cancer risks. Non-smokers with prolonged exposure to secondhand smoke have a 20-30% higher risk than those not exposed (Samet et al., 2009).
3. Exposure to Radon Gas
A decay product of uranium, radon, is a colorless, odorless radioactive gas naturally present in soil. It can seep into homes and accumulate, and prolonged exposure can cause lung cancer. Darby et al. (2005) revealed that radon exposure in homes accounts for a significant percentage of lung cancer cases among non-smokers.
4. Occupational Exposures
Certain professions entail risks due to prolonged exposure to carcinogens. Asbestos, arsenic, diesel exhaust, chromium, nickel and certain chemicals have been linked to lung cancer in workers, especially those who smoke (Stayner et al., 1997). Notably, asbestos exposure can cause mesothelioma, a rare type of lung cancer.
5. Genetic Factors & Family History
Genetic mutations can predispose individuals to lung cancer. Additionally, having a first-degree relative with lung cancer can double or even triple one's risk (Tokuhata & Lilienfeld, 1963). However, distinguishing between inherited risk and shared environmental risk (like smoking in the family) is crucial.
6. Previous radiation therapy
Those who've had radiation therapy to the chest for other cancers have an increased risk of lung cancer (Schaapveld et al., 2015).
7. Air pollution
Prolonged exposure to polluted air can increase the risk of lung cancer. The risk is even higher if one lives in heavily industrialized areas or areas with heavy traffic (Raaschou-Nielsen et al., 2013).
8. Diet and dietary supplements
Some studies suggest that a diet high in fruits and vegetables may protect against lung cancer in both smokers and non-smokers. However, any positive effects from the diet seem to be modest. Beta-carotene supplements have been found to increase the risk of lung cancer in smokers (Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group, 1994).
9. Lung diseases
Certain lung diseases, such as chronic obstructive pulmonary disease (COPD) or pulmonary fibrosis, can increase the risk of lung cancer (Mannino et al., 2008).
While inherent factors can't be changed, understanding and mitigating modifiable risk factors offers a potent tool against the scourge of lung cancer.
Symptoms and Diagnosis
Lung cancer, though sometimes insidious in its onset, gradually reveals an array of symptoms as it progresses. Recognizing and acting upon these signs can significantly enhance diagnostic accuracy and treatment outcomes, emphasizing the imperative of early detection and intervention.
1. Persistent Cough
A protracted cough that intensifies or doesn’t resolve is a cardinal symptom. An observational study in Thorax found that coughing, especially when persistent, was a dominant symptom in lung cancer patients, appearing in over 57% of the cases (Corner et al., 2005).
2. Hemoptysis (Coughing Up Blood)
The presence of blood in sputum is concerning and necessitates urgent medical attention. Studies in the European Respiratory Journal emphasize its diagnostic value, associating it with a high likelihood of malignancy (Smith et al., 2009).
3. Chest Pain
Pain or discomfort in the chest or shoulder, particularly during deep breaths or coughing, may indicate the presence of a growing tumor. This symptom's significance is underscored in a comprehensive review in The Lancet Oncology (Shepherd et al., 2005).
4. Shortness of Breath
As noted in the American Journal of Respiratory and Critical Care Medicine, dyspnea may result from lung tumors impeding airways or from pleural effusion, a condition where fluid accumulates around the lungs (Heffner et al., 2000)
5. Hoarseness
Changes in voice quality, especially persistent hoarseness, may be linked to tumor-induced nerve damage, as highlighted in a study from Chest (Gazdar & Minna, 2008).
6. Unexplained Weight Loss
A drastic, unanticipated weight reduction can indicate various cancers, including lung. A study in the Journal of Clinical Oncology reiterated the clinical significance of this symptom (Fearon et al., 2011).
7. Recurring Respiratory Infections
According to the British Journal of Cancer, frequent infections such as bronchitis or pneumonia may signal obstructed airways due to tumor presence (Hamilton et al., 2005).
Importance of Prompt Action
Symptoms such as these, while not solely indicative of lung cancer, should invariably compel individuals to seek medical assessment. According to the Annals of Oncology, early-stage diagnosis can enhance the 5-year survival rate significantly compared to diagnoses at advanced stages (Oudkerk et al., 2017). Vigilance and prompt medical consultation cannot be overstressed.
Prevention
The old adage "prevention is better than cure" remains deeply resonant, especially in the realm of oncology. Lung cancer, which is accountable for a significant portion of cancer-related mortalities worldwide, is also one where preventive measures can dramatically decrease incidence rates.
1. Avoiding Smoking
Smoking is unequivocally the leading cause of lung cancer, contributing to nearly 85% of all cases (Doll & Hill, 1956). Those who haven't started are advised to abstain, while current smokers should seek cessation resources. Quitting smoking, irrespective of age, can significantly reduce one's risk.
2. Limit Exposure to Secondhand Smoke
Non-smokers exposed to secondhand smoke at home or work increase their risk of lung cancer by 20-30%. It's paramount to avoid environments where smoking is prevalent (Taylor et al., 2007).
3. Radon Gas Testing
Radon, a naturally occurring radioactive gas, is the second leading cause of lung cancer. Homes, especially those in radon-prone areas, should be tested and, if necessary, radon mitigation systems should be installed (Darby et al., 2005).
4. Minimise Occupational Exposure
Prolonged exposure to carcinogens like asbestos, arsenic, and diesel exhaust in the workplace heightens lung cancer risk. Using protective equipment and ensuring that workspaces meet safety standards can mitigate these risks (Loomis et al., 2018).
5. Maintain a Healthy Lifestyle
Preliminary evidence suggests diets rich in fruits and vegetables may offer a protective advantage against lung cancer (Lam et al., 2009). Regular exercise and maintaining a healthy weight also offer general health benefits.
6. Lung Cancer Screening
For individuals at heightened risk, especially current or former smokers aged 55 to 80 with a substantial smoking history, periodic low-dose CT scans have been shown to reduce lung cancer mortality by detecting cancers at more treatable stages (De Koning et al., 2020).
The Power of Proactivity
While some risk factors such as genetics are beyond our control, many actionable steps can be taken to significantly reduce the risk of lung cancer. The advantage of early detection and intervention cannot be overstated; survival rates increase manifold when lung cancer is identified in nascent stages. As science and medicine advance, the adroit combination of preventive measures and early detection can change the narrative, transitioning lung cancer from a feared diagnosis to a manageable condition.
Treatment Options
Navigating the intricacies of lung cancer treatment necessitates a comprehensive, patient-centric approach. Over the past few decades, advancements in oncology have yielded a spectrum of efficacious treatment modalities, enhancing prognosis, symptom management, and overall life quality for patients.
1. Surgery
This involves the removal of the tumor and the surrounding tissue. Depending on the tumor's size, location, and extent, different surgical procedures such as lobectomy, pneumonectomy, or segmentectomy might be recommended. A study in the Journal of Thoracic Oncology highlights the improved survival rates associated with surgical intervention in early-stage non-small cell lung cancer (Goldstraw et al., 2016).
2. Radiation Therapy
Employing high doses of radiation, this therapy targets and eradicates cancer cells. Especially useful for patients who aren't surgical candidates, radiation can be curative or palliative in intent, as demonstrated in The Lancet Oncology (Fairchild et al., 2008).
3. Chemotherapy
Using anti-cancer drugs to kill or impede the growth of rapidly dividing cancer cells, chemotherapy can be applied before surgery (neoadjuvant) or post-surgery (adjuvant), as well as being the main treatment for more advanced stages. Its role in improving prognosis is substantiated in the Journal of Clinical Oncology (Pignon et al., 2008).
4. Targeted Therapy
Tailored to combat specific mutations in lung cancer cells, targeted therapies can block tumor growth and spread with potentially fewer side effects than conventional chemotherapy. A pivotal article in the New England Journal of Medicine demonstrates the promise of these therapies (Lynch et al., 2004).
5. Immunotherapy
This novel approach boosts the body's natural defenses to combat cancer. By helping the immune system recognize and eradicate cancer cells, immunotherapy has shown significant promise, especially in advanced NSCLC as shown in the Journal of the American Medical Association (Reck et al., 2016).
Goals & Tailored Treatment
The overarching goals of lung cancer treatment encompass tumor control, mitigation of symptoms, and the enhancement of patients' quality of life. Individualized treatment plans, tailored to the specific type, stage, and genetic makeup of the cancer, as well as the patient's overall health and preferences, have proven indispensable. As explicated in the *Annals of Thoracic Medicine*, this personalized approach optimizes outcomes, ensuring that patients receive the most effective, least invasive, and best-tolerated therapies for their specific scenario (Tessari et al., 2013).
The Role of Physiotherapy in Lung Cancer Management
The multifaceted landscape of lung cancer management goes beyond surgical interventions and pharmaceutical approaches. Physiotherapy, often an unsung component of holistic cancer care, plays a pivotal role in supporting patients both during and post-treatment.
1. Synergy with Cancer Treatment
Keilor Road Physiotherapy treatment dovetails with conventional cancer treatments by mitigating side effects, promoting functional capacity, and enhancing overall physical resilience. A study in the European Journal of Cancer Care underscores the significant role of physiotherapy in facilitating early postoperative recovery in lung cancer patients (Cabilan & Hines, 2017).
2. Promotion of Exercise
Physical activity is pivotal in counteracting the detrimental impacts of cancer treatments on muscle mass, bone density, and cardiovascular health. Customised exercise programs here at Keilor Road Physiotherapy, can curtail cancer-related fatigue, improve mood, and bolster general wellbeing (Brown et al., 2012).
3. Breathing Exercises and Respiratory Function
Given the pulmonary implications of lung cancer, physiotherapists are instrumental in teaching patients breathing techniques that maximise lung function, reduce breathlessness, and improve oxygenation. Such interventions are supported by findings in the Respiratory Medicine Journal (Borge et al., 2014).
4. Energy Conservation and Fatigue Management
Fatigue is a ubiquitous challenge in lung cancer patients. Keilor Road Physiotherapy aims to equip patients with energy conservation techniques, ensuring that daily activities are executed with minimal exertion. This approach enhances functional capacity and autonomy, as detailed in the Journal of Physiotherapy (Cheville et al., 2013).
5. Holistic Well-being and Support
Beyond physical exercises, physiotherapists offer psychosocial support, helping patients navigate the emotional turbulence of a cancer diagnosis and its ramifications. The therapeutic alliance fosters resilience, hope, and empowerment.
Individualised Approach
Each lung cancer patient presents with unique challenges, making personalised care paramount. At Keilor Road Physiotherapy, we craft bespoke exercise regimens, breathing strategies, and energy conservation protocols, harmonising with the patient's specific needs, co-morbidities, and treatment trajectory.
Supportive Care and Survivorship
The journey through lung cancer extends beyond the realm of diagnosis and treatment, delving deeply into the post-treatment phase that emphasises healing, adaptation, and revitalisation. Supportive care and a focus on survivorship play indispensable roles in this continuum, ensuring that the patient not only survives but thrives.
1. Integral Role of Supportive Care
As evidenced in the Journal of Clinical Oncology, supportive care, encompassing psychosocial support, nutritional guidance, pain management, and symptom control, has been shown to improve patient outcomes and quality of life (Temel et al., 2010). Navigating the emotional, physical, and psychological aftermath of a lung cancer diagnosis necessitates a holistic, patient-centric approach.
2. Physiotherapy in Survivorship
The role of physiotherapy does not wane post-treatment. On the contrary, it burgeons in significance. Keilor Road Physiotherapy looks to optimise functional capacity, hastening recovery, and facilitating a smooth transition into survivorship. A study in the Physical Therapy Journal delineates how tailored physical interventions bolster physical function and attenuate post-treatment fatigue in lung cancer survivors (Granger et al., 2013).
3. Support Groups and Rehabilitation
Support groups, by fostering a sense of community and shared experience, can be a beacon for many, as they grapple with the repercussions of their diagnosis. Furthermore, rehabilitation programs, tailored to the specific needs of lung cancer survivors, can be instrumental in restoring physical function, enhancing psychological well-being, and fostering social reintegration, as noted in the European Respiratory Journal (Spruit et al., 2013).
4. Resources for Patients and Caregivers
The toll of lung cancer isn't borne by patients alone; caregivers too face a myriad of challenges. Resources such as informational materials, workshops, and counselling services can equip caregivers with the requisite tools to support their loved ones while ensuring their own well-being, as highlighted in the Cancer Journal (Kim et al., 2014).
Conclusion
Lung cancer, given its noteworthy prevalence in Australia and its position as one of the top five cancers diagnosed (Australian Institute of Health and Welfare, 2020), demands meticulous attention and comprehensive understanding. Through the course of this discourse, we have delved into the intricate dimensions of lung cancer, its myriad manifestations, therapeutic modalities, and the integral role of physiotherapy.
To encapsulate the key points:
1.Lung Cancer Cognizance
A profound comprehension of the pathology – its genesis, classifications, clinical manifestations, and predisposing factors – is indispensable for patients and healthcare providers to formulate evidence-based therapeutic strategies.
2. Therapeutic Modalities
Traditional treatments like surgery, radiation, and chemotherapy remain pivotal. However, the advent of modalities such as targeted therapy and immunotherapy have expanded the therapeutic horizon.
3. Physiotherapy: An Essential Adjunct
Throughout the therapeutic continuum of lung cancer, physiotherapy emerges as a quintessential adjunct, alleviating symptomatology, augmenting functional outcomes, and fostering holistic patient well-being.
4. Supportive Care: An Imperative for Enhanced Survivorship
Beyond the ambit of clinical remission lies the realm of quality-assured survivorship, fortified by psychosocial interventions, rehabilitative endeavors, and survivorship programs.
The trajectory of lung cancer care has been progressively evolving, underpinned by advancements in medical research and a heightened emphasis on proactive detection and comprehensive management. Although statistical data paints a formidable picture, they are juxtaposed against the backdrop of human fortitude and a multifaceted care paradigm, as documented in *The Lancet Oncology* (Allemani et al., 2018). Particularly in developed regions such as Australia, lung cancer prognoses have witnessed marked amelioration.
While the challenges posed by lung cancer are significant, they are far from insurmountable. Armed with knowledge, integrative care approaches, and the cumulative advancements of medical science, the prospect of surmounting this malignancy grows increasingly favorable.
References:
Allemani, C., Matsuda, T., Di Carlo, V., Harewood, R., Matz, M., Nikšić, M., ... & Bonaventure, A. (2018). Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. *The Lancet Oncology*, 19(3), 290-303.
Australian Institute of Health and Welfare. (2020). *Cancer data in Australia*. AIHW.Borge, C. R., Hagen, K. B., Mengshoel, A. M., Omenaas, E., Moum, T., & Wahl, A. K. (2014). Effects of controlled breathing exercises and respiratory muscle training in people with chronic obstructive pulmonary disease: results from evaluating the quality of evidence in systematic reviews. BMC pulmonary medicine, 14, 184. https://doi.org/10.1186/1471-2466-14-184
Brown, J. C., Winters-Stone, K., Lee, A., & Schmitz, K. H. (2012). Cancer, physical activity, and exercise. Comprehensive Physiology, 2(4), 2775–2809. https://doi.org/10.1002/cphy.c120005Cabilan, C. J., & Hines, S. (2017). The short-term impact of colorectal cancer treatment on physical activity, functional status and quality of life: a systematic review. JBI database of systematic reviews and implementation reports, 15(2), 517–566. https://doi.org/10.11124/JBISRIR-2016003282
Cavalheri, V., Tahirah, F., Nonoyama, M., Jenkins, S., & Hill, K. (2014). Exercise training for people following lung resection for non-small cell lung cancer - a Cochrane systematic review. Cancer treatment reviews, 40(4), 585–594. https://doi.org/10.1016/j.ctrv.2013.11.001
Cheville, A. L., Kollasch, J., Vandenberg, J., Shen, T., Grothey, A., Gamble, G., & Basford, J. R. (2013). A home-based exercise program to improve function, fatigue, and sleep quality in patients with Stage IV lung and colorectal cancer: a randomized controlled trial. Journal of pain and symptom management, 45(5), 811–821. https://doi.org/10.1016/j.jpainsymman.2012.05.006
Corner, J., Hopkinson, J., Fitzsimmons, D., Barclay, S., & Muers, M. (2005). Is late diagnosis of lung cancer inevitable? Interview study of patients' recollections of symptoms before diagnosis. Thorax, 60(4), 314–319. https://doi.org/10.1136/thx.2004.029264
Darby, S., Hill, D., Auvinen, A., Barros-Dios, J. M., Baysson, H., Bochicchio, F., ... & Kreienbrock, L. (2005). Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies. *British Medical Journal*, 330(7485), 223.
De Koning, H. J., Van Der Aalst, C. M., De Jong, P. A., Scholten, E. T., Nackaerts, K., Heuvelmans, M. A., ... & Prokop, M. (2020). Reduced lung-cancer mortality with volume CT screening in a randomized trial. *New England Journal of Medicine*, 382(6), 503-513.
Doll, R., & Hill, A. B. (1956). Lung cancer and other causes of death in relation to smoking; a second report on the mortality of British doctors. *British Medical Journal*, 2(5001), 1071.
Fairchild, A., Harris, K., Barnes, E., Wong, R., Lutz, S., Bezjak, A., Cheung, P., & Chow, E. (2008). Palliative thoracic radiotherapy for lung cancer: a systematic review. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26(24), 4001–4011. https://doi.org/10.1200/JCO.2007.15.3312
Fearon, K., Strasser, F., Anker, S. D., Bosaeus, I., Bruera, E., Fainsinger, R. L., Jatoi, A., Loprinzi, C., MacDonald, N., Mantovani, G., Davis, M., Muscaritoli, M., Ottery, F., Radbruch, L., Ravasco, P., Walsh, D., Wilcock, A., Kaasa, S., & Baracos, V. E. (2011). Definition and classification of cancer cachexia: an international consensus. The Lancet. Oncology, 12(5), 489–495. https://doi.org/10.1016/S1470-2045(10)70218-7
Field JK, Duffy SW. (2008). Lung cancer screening: the way forward. *British Journal of Cancer*, 99(4), 557-562.Gazdar, A. F., & Minna, J. D. (2008). Deregulated EGFR signaling during lung cancer progression: mutations, amplicons, and autocrine loops. Cancer prevention research (Philadelphia, Pa.), 1(3), 156–160. https://doi.org/10.1158/1940-6207.CAPR-08-0080
Goldstraw, P., Chansky, K., Crowley, J., Rami-Porta, R., Asamura, H., Eberhardt, W. E., ... & Vokes, E. E. (2016). The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. *Journal of Thoracic Oncology*, 11(1), 39-51.
Granger, C. L., McDonald, C. F., Parry, S. M., Oliveira, C. C., & Denehy, L. (2013). Functional capacity, physical activity and muscle strength assessment of individuals with non-small cell lung cancer: a systematic review of instruments and their measurement properties. BMC cancer, 13, 135. https://doi.org/10.1186/1471-2407-13-135
Hamilton, W., Peters, T. J., Round, A., & Sharp, D. (2005). What are the clinical features of lung cancer before the diagnosis is made? A population based case-control study. Thorax, 60(12), 1059–1065. https://doi.org/10.1136/thx.2005.045880Hecht, S.S. (2012). Lung carcinogenesis by tobacco smoke. *International Journal of Cancer*, 131(12), 2724-2732.
Heffner, J. E., Nietert, P. J., & Barbieri, C. (2000). Pleural fluid pH as a predictor of survival for patients with malignant pleural effusions. Chest, 117(1), 79–86. https://doi.org/10.1378/chest.117.1.79
Kim, Y., Shaffer, K. M., Carver, C. S., & Cannady, R. S. (2014). Prevalence and predictors of depressive symptoms among cancer caregivers 5 years after the relative's cancer diagnosis. Journal of consulting and clinical psychology, 82(1), 1–8. https://doi.org/10.1037/a0035116
Lam, T. K., Cross, A. J., Consonni, D., Randi, G., Bagnardi, V., Bertazzi, P. A., ... & Sinha, R. (2009). Intakes of red meat, processed meat, and meat mutagens increase lung cancer risk. *Cancer Research*, 69(3), 932-939.
Loomis, D., Guha, N., Hall, A. L., Straif, K. (2018). Identifying occupational carcinogens: an update from the IARC Monographs. *Occupational & Environmental Medicine*, 75(8), 593-603.
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., ... & Settleman, J. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib. *New England Journal of Medicine*, 350(21), 2129-2139.
Mannino, D.M., Aguayo, S.M., Petty, T.L., & Redd, S.C. (2003). Low lung function and incident lung cancer in the United States: data from the First National Health and Nutrition Examination Survey follow-up. *Archives of Internal Medicine*, 163(12), 1475-1480.
Oser, M.G., Niederst, M.J., Sequist, L.V., & Engelman, J.A. (2015). Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. *The Lancet Oncology*, 16(4), e165-e172.
Oudkerk, M., Devaraj, A., Vliegenthart, R., Henzler, T., Prosch, H., Heussel, C. P., ... & Sverzellati, N. (2017). European position statement on lung cancer screening. *Annals of Oncology*, 28(11), 2807-2816.
Pignon, J. P., Tribodet, H., Scagliotti, G. V., Douillard, J. Y., Shepherd, F. A., Stephens, R. J., ... & Le Chevalier, T. (2008). Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. *Journal of Clinical Oncology*, 26(21), 3552-3559.
Raaschou-Nielsen, O., Andersen, Z.J., Beelen, R., Samoli, E., Stafoggia, M., Weinmayr, G., ... & Dimakopoulou, K. (2013). Air pollution and lung cancer incidence in 17 European cohorts: prospective analyses from the European Study of Cohorts for Air Pollution Effects (ESCAPE). *The Lancet Oncology*, 14(9), 813-822.
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., O'Brien, M., Rao, S., Hotta, K., Leiby, M. A., Lubiniecki, G. M., Shentu, Y., Rangwala, R., Brahmer, J. R., & KEYNOTE-024 Investigators (2016). Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. The New England journal of medicine, 375(19), 1823–1833. https://doi.org/10.1056/NEJMoa1606774
Samet, J.M., Avila-Tang, E., Boffetta, P., Hannan, L.M., Olivo-Marston, S., Thun, M.J., & Rudin, C.M. (2009). Lung cancer in never smokers: clinical epidemiology and environmental risk factors. *Clinical Cancer Research*, 15(18), 5626-5645.
Schaapveld, M., Aleman, B.M., van Eggermond, A.M., Janus, C.P., Krol, A.D., van der Maazen, R.W., ... & Daniels, L.A. (2015). Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma. *New England Journal of Medicine*, 373(26), 2499-2511.
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., van Kooten, M., Dediu, M., Findlay, B., Tu, D., Johnston, D., Bezjak, A., Clark, G., Santabárbara, P., Seymour, L., & National Cancer Institute of Canada Clinical Trials Group (2005). Erlotinib in previously treated non-small-cell lung cancer. The New England journal of medicine, 353(2), 123–132. https://doi.org/10.1056/NEJMoa050753
Smith, S. M., Campbell, N. C., MacLeod, U., Lee, A. J., Raja, A., Wyke, S., Ziebland, S. B., Duff, E. M., Ritchie, L. D., & Nicolson, M. C. (2009). Factors contributing to the time taken to consult with symptoms of lung cancer: a cross-sectional study. Thorax, 64(6), 523–531. https://doi.org/10.1136/thx.2008.096560
Spruit, M. A., Singh, S. J., Garvey, C., ZuWallack, R., Nici, L., Rochester, C., ... & Clini, E. M. (2013). An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. *American Journal of Respiratory and Critical Care Medicine*, 188(8), e13-e64.
Stayner, L., Smith, R., Bailer, J., Gilbert, S., Steenland, K., Dement, J., ... & Lemen, R. (1997). Exposure-response analysis of risk of respiratory disease associated with occupational exposure to chrysotile asbestos. *Occupational and Environmental Medicine*, 54(9), 646-652.
Taylor, R., Najafi, F., & Dobson, A. (2007). Meta-analysis of studies of passive smoking and lung cancer: effects of study type and continent. International journal of epidemiology, 36(5), 1048–1059. https://doi.org/10.1093/ije/dym158
Temel, J. S., Greer, J. A., Muzikansky, A., Gallagher, E. R., Admane, S., Jackson, V. A., Dahlin, C. M., Blinderman, C. D., Jacobsen, J., Pirl, W. F., Billings, J. A., & Lynch, T. J. (2010). Early palliative care for patients with metastatic non-small-cell lung cancer. The New England journal of medicine, 363(8), 733–742. https://doi.org/10.1056/NEJMoa1000678
Tessari, A., Palmieri, D., & Di Cosimo, S. (2013). Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients. Pharmacogenomics and personalized medicine, 7, 1–19. https://doi.org/10.2147/PGPM.S53304
The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. (1994). The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. *New England Journal of Medicine*, 330(15), 1029-1035.
Thun, M.J., Carter, B.D., Feskanich, D., Freedman, N.D., Prentice, R., Lopez, A.D., ... & Gapstur, S.M. (2013). 50-year trends in smoking-related mortality in the United States. *New England Journal of Medicine*, 368(4), 351-364.
Tokuhata, G.K., & Lilienfeld, A.M. (1963). Familial aggregation of lung cancer in humans. *Journal of the National Cancer Institute*, 30(2), 289-312.
Travis, W.D., Brambilla, E., Nicholson, A.G., Yatabe, Y., Austin, J.H.M., Beasley, M.B., ... & Dacic, S. (2015). The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. *Journal of Thoracic Oncology*, 10(9), 1243-1260.
Article by
John Keller
Clinical Director | Sports & Musculoskeletal Physiotherapist
John graduated as a Physiotherapist from the Auckland University of Technology with the John Morris memorial prize for outstanding clinical practise in 2003. John has since completed Post Graduate Diplomas in both Sports Medicine and Musculoskeletal Physiotherapy with distinction, also collecting the Searle Shield for excellence in Musculoskeletal Physiotherapy.
Reviewed by
Dr. Jenny Hynes FACP
Clinical Director | Specialist Musculoskeletal Physiotherapist
Jenny sat extensive examinations to be inducted as a fellow into the Australian College of Physiotherapy in 2009 and gain the title of Specialist Musculoskeletal Physiotherapist, one of only a few physiotherapists in the state to have done so.